Clinical Trial

XTX301 in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2023-01-06; most recent amendment 2026-06-18.
Status change: Not Yet Recruiting → Recruiting 2023-01-30
Trial Details
NCT Number NCT05684965
Lead Sponsor Xilio Development, Inc.
Conditions Advanced Solid Tumor
Enrollment 358 participants
Start Date 2023-05-11
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-23